Evidence map›Paper›PMID 39779631›Full record

ArticleDrug safety2025

Pharmacovigilance in the Community: A Special-Interest Group of the International Society of Pharmacovigilance.

Mohamed A Elhawary, Rebecca Noss, Loubna Alj, Manal Younus, Mayada Alkhakany, Hadir Rostom, Angela Caro-Rojas, Thamir M Alshammari

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohamed A ElhawaryEgyptian Ministry of Health and Population, Expanded Programme on Immunization (General Secretary of ISoP Egypt Chapter), Cairo, Egypt. mohamed.ahmed.elhawary19@gmail.com.ORCID http://orcid.org/0000-0002-4043-6867
Rebecca NossNoss Research Consulting LLC (Chair of the ISoP PV in the Community SIG), Columbus, OH, USA.ORCID http://orcid.org/0009-0009-0006-3515
Loubna AljCentre Anti Poison et de Pharmacovigilance du Maroc, Ministry of Health and Social Protection, Rabat, Morocco.ORCID http://orcid.org/0000-0001-5464-378X
Manal YounusIraqi Pharmacovigilance Centre, Ministry of Health (Vice President of ISoP Middle East Chapter), Baghdad, Iraq.ORCID http://orcid.org/0000-0001-9475-5700
Mayada AlkhakanyISoP Patient Engagement SIG, London, UK.ORCID http://orcid.org/0000-0002-1634-2246
Hadir RostomInternational Society of Pharmacovigilance (ISoP) , Egypt Chapter, Cairo, Egypt.ORCID http://orcid.org/0000-0003-3872-0540
Angela Caro-RojasPontificia Universidad Javeriana (President of ISoP), Bogotá, Colombia.ORCID http://orcid.org/0000-0001-9773-7188
Thamir M AlshammariInternational Society of Pharmacovigilance, Middle East Chapter, Dubai, UAE.ORCID http://orcid.org/0000-0002-5630-2468

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39779631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.